Clinical Trials on Burns Multiple in Switzerland

Total 252 results

Stichting European Myeloma Network
Janssen Pharmaceutica

Recruiting

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4)

Multiple Myeloma

United Kingdom, Czechia, Australia, Austria, Belgium, Denmark, Germany, Greece, Italy, Netherlands, Norway, Serbia, Switzerland, Turkey, Brazil
Novartis Pharmaceuticals

Completed

Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis

Relapsing Forms of Multiple Sclerosis

Germany, South Africa, Italy, United States, Austria, Belgium, Czechia, Egypt, Hungary, Malaysia, Turkey, Spain, Australia, Canada, France, Israel, Netherlands, Switzerland, Greece, Korea, Republic of, Romania, Russian Federation, United... and more
Novartis Pharmaceuticals

Completed

Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis (OCTIMS)

Multiple Sclerosis | RRMS

Spain, Czechia, Germany, Australia, Italy, Switzerland, Denmark, United States, United Kingdom, Canada, Netherlands, Poland
Biogen

Terminated

Feasibility of the Multiple Sclerosis Performance Test in Participants With Multiple Sclerosis

Multiple Sclerosis

United States, Italy, Switzerland, United Kingdom, Czechia, France
European Organisation for Research and Treatment...

Completed

Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count

Lymphoma | Unspecified Childhood Solid Tumor, Protocol Specific | Myelodysplastic Syndromes | Leukemia | Unspecified Adult Solid Tumor, Protocol Specific | Infection | Multiple Myeloma and Plasma Cell Neoplasm | Fever, Sweats, and Hot Flashes | Bone Marrow Suppression

Switzerland, United States, Canada, United Kingdom, Belgium, Israel, Slovakia, Finland, Germany, France, Turkey, Czech Republic, Greece
Sanofi

Completed

A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis (TENERE)

Multiple Sclerosis

Hungary, Belgium, Germany, Italy, Greece, France, Poland, Spain, Canada, Switzerland, Czech Republic, Tunisia, United Kingdom
Bayer

Completed

BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies

Multiple Sclerosis

Spain, Belgium, Czechia, Italy, United Kingdom, Hungary, Germany, Switzerland, Austria, France, Poland, Canada, Sweden, Finland, Israel, Denmark, Norway, Portugal
Biogen

Completed

Persistence, Adherence, Quality of Life, and Treatment Satisfaction With Avonex® PEN™. (PERSIST)

Multiple Sclerosis

Sweden, France, United Kingdom, Germany, Denmark, Netherlands, Slovakia, Switzerland, Norway, Portugal
Australian and New Zealand Intensive Care Research...
Monash University; University College Dublin; Health Research Board, Ireland; Health... and other collaborators

Recruiting

ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients (EPO-TRAUMA)

Wounds and Injuries | Trauma | Traumatic Brain Injury | Multiple Trauma | Major Trauma | Traumatic Injury | Penetrating Injury | Blunt Injury

Australia, Ireland, Finland, New Zealand, Slovenia, Germany, Saudi Arabia, Switzerland
Bayer

Completed

Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis

Multiple Sclerosis

Belgium, Italy, Spain, France, Switzerland, Israel, Czech Republic, Canada, Austria, Poland, Germany, Netherlands, United Kingdom, Hungary, Portugal, Finland, Norway, Sweden, Slovenia, Denmark
Novartis Pharmaceuticals

Recruiting

The Gilenya Pregnancy Registry

Multiple Sclerosis

Denmark, Spain, Switzerland, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Colombia, Cyprus, Czechia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Lebanon, Mexico, Netherlands, Norway, Poland, ... and more
Actelion

Terminated

Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®) (POINT)

Multiple Sclerosis

United States, Germany, Hungary, Poland, United Kingdom, Australia, Austria, Belgium, Bulgaria, Canada, Czechia, Denmark, France, Greece, Italy, Mexico, Portugal, Russian Federation, Spain, Switzerland
Sanofi

Completed

Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis

United States, Austria, Canada, Chile, Czech Republic, Denmark, Estonia, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Portugal, Russian Federation, Sweden, Switzerland, Turkey, Ukraine, United Kingdom
Bayer

Completed

BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study

Multiple Sclerosis

Belgium, Italy, Spain, France, Germany, Canada, Switzerland, Austria, Denmark, Hungary, Netherlands, Poland, Israel, United Kingdom, Finland, Sweden, Norway, Czech Republic, Portugal, Slovenia
Boehringer Ingelheim

Recruiting

A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome

Netherton Syndrome

Belgium, United Kingdom, Australia, Germany, China, Malaysia, United States, Japan, France, Israel, Bulgaria, Italy, Finland, Switzerland, Netherlands, Portugal
Mundipharma Research Limited

Active, not recruiting

Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

Multiple Myeloma | Hodgkin's Lymphoma | Hematological Malignancies | Cutaneous T Cell Lymphoma

France, United States, Netherlands, Spain, Switzerland, Germany, Italy
University of Bern
Novartis; University Hospital Inselspital, Berne; Schweizerische Multiple Sklerose... and other collaborators

Recruiting

Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)

Multiple Sclerosis | Optic Neuritis | Neuromyelitis Optica Spectrum Disorder | CNS Sarcoidosis | CNS Vasculitis | Transverse Myelitis | Rasmussen Encephalitis | Acute Disseminated Encephalomyelitis | Anti-NMDAR Encephalitis | Anti-GAD65 Associated Autoimmune Encephalitis | Anti-AMPAR-1/2 Associated Autoimmune... and other conditions

Switzerland
European Society for Blood and Marrow Transplantation
Celgene Corporation; Johnson & Johnson Pharmaceutical Research & Development...

Terminated

MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation

Multiple Myeloma

France, Israel, Germany, Switzerland, Hungary, Czechia, United Kingdom, Austria, Belgium, Italy
Celgene

Completed

A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma

Multiple Myeloma

Spain, United Kingdom, Switzerland, Australia, Israel, Italy, Poland, France, Belgium, Ireland, Austria, Germany, Ukraine, Greece, Sweden
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

Multiple Sclerosis

United States, Argentina, Poland, Canada, Australia, Belgium, Brazil, Denmark, France, Germany, Greece, Hungary, Italy, Peru, Portugal, Russian Federation, Spain, Switzerland, Turkey, Ukraine, United Kingdom
Celgene

Active, not recruiting

Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)

Multiple Myeloma

United States, Belgium, Canada, France, Germany, Italy, Japan, Netherlands, Norway, Spain, Sweden, Switzerland, United Kingdom
University Hospital, Toulouse
Celgene; Intergroupe Francophone du Myelome

Completed

Maintenance Therapy Using Lenalidomide in Myeloma (IFM2005-02)

Myeloma

France, Belgium, Switzerland
Celgene

Completed

Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma

Multiple Myeloma

Canada, Denmark, Australia, Belgium, France, Germany, Italy, Netherlands, Russian Federation, Spain, Sweden, Switzerland, United Kingdom, Czechia, Greece
Biogen

Terminated

Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS) (AFFINITY)

Multiple Sclerosis

United States, Italy, Spain, Belgium, Germany, Switzerland, Australia, Hungary, France, Poland, United Kingdom, Czechia, Israel, Canada, Netherlands
Celgene

Completed

Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma (STRATUS)

Multiple Myeloma

Netherlands, Spain, Belgium, Austria, Switzerland, Italy, Germany, France, Ireland, United Kingdom, Denmark, Finland, Portugal, Turkey, Poland, Estonia, Greece, Norway, Slovakia, Sweden
Novartis Pharmaceuticals

Withdrawn

Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)

Basal Cell Carcinoma

Greece, Switzerland, Germany, United Kingdom, Belgium, Canada, Czechia, Finland, Italy, Spain
Hoffmann-La Roche

Active, not recruiting

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis (OLERO)

Multiple Sclerosis

United States, Spain, Austria, Czechia, Italy, Hungary, Australia, Portugal, Serbia, Canada, Germany, United Kingdom, Poland, Romania, Croatia, Israel, Belgium, Bulgaria, Estonia, Switzerland, Mexico, Lithuania, New Zealand, France, Slo... and more
Stichting European Myeloma Network
Janssen Research & Development, LLC

Recruiting

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (CARTITUDE-6)

Multiple Myeloma

Netherlands, United States, Spain, Belgium, France, Italy, Germany, Japan, Canada, Australia, Sweden, Israel, United Kingdom, Czechia, Greece, Switzerland, Norway
Celgene Corporation

Completed

A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma

Multiple Myeloma

United States, Spain, Australia, Canada, United Kingdom, Italy, Switzerland, Bulgaria, Poland, Ukraine, Belgium, Germany, Hungary, Ireland, Israel, Russian Federation
Biogen

Completed

Dimethyl Fumarate (DMF) Observational Study (ESTEEM)

Multiple Sclerosis

United States, Denmark, Italy, Netherlands, Switzerland, Canada, Australia, New Zealand, United Kingdom, Slovakia, Austria, Hungary, Czechia, Portugal, Germany, Spain, Poland, Puerto Rico, France, Argentina, Ireland, Norway
Janssen Research & Development, LLC

Recruiting

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7)

Multiple Myeloma

Germany, Korea, Republic of, Belgium, Israel, Australia, United Kingdom, France, Sweden, Spain, Turkey, Italy, Japan, Czechia, Brazil, Netherlands, Poland, Portugal, Switzerland, Norway, Greece, China, Canada
Celgene

Completed

A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study (NIMBUS)

Multiple Myeloma

United States, Netherlands, Canada, Belgium, United Kingdom, Australia, Denmark, Germany, Spain, Switzerland, France, Italy, Greece, Russian Federation, Sweden, Czechia
Janssen Research & Development, LLC

Recruiting

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy (CARTITUDE-5)

Multiple Myeloma

United States, Korea, Republic of, Czechia, Israel, Switzerland, Belgium, United Kingdom, Japan, Canada, Spain, Sweden, Germany, Australia, Netherlands, France, Argentina, Brazil, Denmark, Greece, Poland, Ireland, Hungary, Portugal, F... and more
GlaxoSmithKline

Active, not recruiting

Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma (DREAMM 14)

Multiple Myeloma

United States, Taiwan, Poland, Thailand, Germany, France, Ireland, Greece, Korea, Republic of, United Kingdom, Australia, Italy, India, Argentina, Canada, Spain, Switzerland, Brazil, Mexico
Bristol-Myers Squibb
AbbVie

Completed

An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma (CheckMate 602)

Multiple Myeloma

Canada, United States, Israel, Czechia, Switzerland, Greece, Denmark, Portugal, Italy, Germany, Austria, Norway, Puerto Rico, Spain, Sweden, Turkey
Stichting Hemato-Oncologie voor Volwassenen Nederland
European Myeloma Network; Gruppo Italiano Malattie EMatologiche dell'Adulto; DSMM... and other collaborators

Active, not recruiting

Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma (HO95)

Multiple Myeloma

Sweden, Norway, Italy, Netherlands, Belgium, Switzerland, Australia, Denmark, Finland, Czechia, Turkey, Austria, Luxembourg, Hungary, Greece, Portugal
Amgen
Daiichi Sankyo, Inc.

Completed

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma

Cancer | Multiple Myeloma | Bone Metastases | Hematologic Malignancies | Oncology | Multiple Myeloma Bone Lesions

United States, Germany, Italy, Spain, Canada, France, Czechia, Hungary, Korea, Republic of, Russian Federation, United Kingdom, Taiwan, Australia, Hong Kong, New Zealand, Austria, Slovakia, Portugal, Greece, Bulgaria, Poland, Ukraine and more
Bristol-Myers Squibb
AbbVie

Completed

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma (ELOQUENT - 1)

Multiple Myeloma

United States, Australia, Austria, Belgium, Canada, Czechia, Germany, Greece, Hungary, Ireland, Israel, Italy, Poland, Puerto Rico, Romania, Russian Federation, Spain, Switzerland, Turkey, United Kingdom
Pfizer

Completed

Bosutinib For Autosomal Dominant Polycystic Kidney Disease

Polycystic Kidney, Autosomal Dominant

United States, Canada, Australia, Sweden, Spain, Poland, Korea, Republic of, Switzerland, United Kingdom, Moldova, Republic of, Italy, Czech Republic, Hungary, Lithuania, Romania, Slovakia, Turkey
Sanofi

Recruiting

A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) (IONA-MM)

Plasma Cell Myeloma

Germany, United States, Argentina, China, France, Hong Kong, Italy, Japan, Puerto Rico, Spain, Switzerland, United Arab Emirates, United Kingdom, Austria, Belgium, Netherlands, Taiwan
Amgen

Completed

Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma (CLARION)

Multiple Myeloma

Korea, Republic of, China, Spain, Taiwan, United States, Netherlands, Australia, Singapore, New Zealand, United Kingdom, Israel, France, Japan, Italy, Czechia, Belgium, Argentina, Austria, Bulgaria, Canada, Germany, Greece, Hungary, M... and more
Celgene

Recruiting

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (EXCALIBER-RRMM)

Multiple Myeloma

Austria, Italy, China, Australia, Spain, United States, Korea, Republic of, Taiwan, Germany, Ireland, Argentina, Brazil, Mexico, Netherlands, Belgium, Czechia, France, Greece, Japan, Poland, Israel, United Kingdom, Norway, Denmark, Finland and more
Bristol-Myers Squibb

Recruiting

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

Canada, Taiwan, United States, Australia, Denmark, China, Korea, Republic of, Israel, Spain, France, Germany, Czechia, Austria, Japan, Sweden, United Kingdom, Greece, Italy, Finland, Argentina, Belgium, Brazil, Colombia, Hong Kong, India, Mexic... and more
Bristol-Myers Squibb
AbbVie

Completed

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma (ELOQUENT - 2)

Lymphoma | Multiple Myeloma

United States, Belgium, France, Germany, Italy, Japan, United Kingdom, Australia, Poland, Puerto Rico, Canada, Denmark, Hungary, Israel, Spain, Czechia, Ireland, Austria, Switzerland, Greece, Turkey, Romania, United Arab Emirates
Celgene

Withdrawn

A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (ALUMMINATE)

Multiple Myeloma

China, Australia, United States, Argentina, Austria, Belgium, Brazil, Canada, Chile, Czechia, France, Germany, Greece, Hungary, India, Ireland, Italy, Japan, Korea, Republic of, Norway, Portugal, Romania, Spain, Sweden, Switzerland, Turkey, United Kingdom
Takeda

Completed

A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)

Multiple Myeloma

France, Spain, United States, Taiwan, Korea, Republic of, Israel, Australia, Czechia, Hungary, Canada, Japan, Portugal, Singapore, United Kingdom, Italy, Sweden, Poland, Germany, China, Denmark, Greece, Thailand, Serbia, Turkey, Colombia, Russian Federation and more
Celgene

Completed

Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma (FIRST)

Multiple Myeloma

Korea, Republic of, United States, France, Belgium, Canada, Spain, United Kingdom, Australia, Italy, New Zealand, China, Portugal, Switzerland, Taiwan, Austria, Greece, Germany, Ireland, Sweden
Takeda

Active, not recruiting

A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant

Multiple Myeloma | Autologous Stem Cell Transplant

United States, Spain, Australia, Czechia, Hungary, Taiwan, Italy, Denmark, Portugal, Singapore, Israel, Canada, France, Belgium, United Kingdom, Germany, Japan, Austria, Netherlands, Korea, Republic of, Poland, Greece, Colombia, Sweden, South Africa and more
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States, Canada, Puerto Rico, Australia, Netherlands, New Zealand, Switzerland
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease (OVERTURE)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

United States, Argentina, Australia, Belgium, Brazil, Canada, Czech Republic, France, Germany, Italy, Japan, Netherlands, Norway, Poland, Romania, Spain, Sweden, Switzerland, Turkey, United Kingdom

Clinical Trials on Burns Multiple in Switzerland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Egypt

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations